A detailed history of Godsey & Gibb Associates transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Godsey & Gibb Associates holds 455 shares of BMY stock, worth $25,580. This represents 0.0% of its overall portfolio holdings.

Number of Shares
455
Previous 1,634 72.15%
Holding current value
$25,580
Previous $67,000 65.67%
% of portfolio
0.0%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$39.66 - $51.75 $46,759 - $61,013
-1,179 Reduced 72.15%
455 $23,000
Q2 2024

Jul 23, 2024

BUY
$40.25 - $52.99 $60,737 - $79,961
1,509 Added 1207.2%
1,634 $67,000
Q1 2024

Apr 23, 2024

SELL
$47.98 - $54.4 $14,393 - $16,320
-300 Reduced 70.59%
125 $6,000
Q4 2023

Jan 16, 2024

SELL
$48.48 - $57.85 $14,543 - $17,355
-300 Reduced 41.38%
425 $21,000
Q4 2022

Jan 18, 2023

BUY
$68.48 - $81.09 $49,648 - $58,790
725 New
725 $0
Q1 2021

May 13, 2021

SELL
$59.34 - $66.74 $213,149 - $239,730
-3,592 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$57.74 - $65.43 $207,402 - $235,024
3,592 New
3,592 $223,000
Q3 2020

Nov 10, 2020

SELL
$57.43 - $63.64 $318,736 - $353,202
-5,550 Closed
0 $0
Q2 2020

Aug 12, 2020

BUY
$54.82 - $64.09 $74,007 - $86,521
1,350 Added 32.14%
5,550 $326,000
Q1 2020

May 11, 2020

BUY
$46.4 - $67.43 $13,920 - $20,229
300 Added 7.69%
4,200 $234,000
Q4 2019

Feb 06, 2020

SELL
$49.21 - $64.19 $7,381 - $9,628
-150 Reduced 3.7%
3,900 $250,000
Q3 2019

Nov 13, 2019

SELL
$42.77 - $50.71 $30,452 - $36,105
-712 Reduced 14.95%
4,050 $205,000
Q2 2019

Aug 07, 2019

BUY
$44.62 - $49.34 $212,480 - $234,957
4,762 New
4,762 $216,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $120B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Godsey & Gibb Associates Portfolio

Follow Godsey & Gibb Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Godsey & Gibb Associates, based on Form 13F filings with the SEC.

News

Stay updated on Godsey & Gibb Associates with notifications on news.